Breast cancer: a new imaging approach as an addition to existing guidelines

Worldwide breast cancer has the highest incidence of all malignancies in women. Although the incidence has increased, mortality has decreased during the last two decades [1]. This reduction in mortality is largely due to early detection of malignancies in screening and to better and more personalized therapies [2]. Mammography is the primary screening imaging modality. This technique, however, has limitations in terms of sensitivity (39–86 %) and specificity (88–94 %), depending on age and breast density [3, 4]. Therefore, ultrasound is used in addition to mammography to increase diagnostic accuracy [5]. Mammography is scored in five categories according to the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS): category 1, negative; 2, benign finding; 3, probably benign; 4, suspicious finding (chance of malignancy 2–95 %); and 5, highly suggestive of malignancy (chance of malignancy >95 %) [6]. The guideline for non-invasive diagnostic tests for breast abnormalities of the Agency for Healthcare Research and Quality (AHRQ) in the USA states that for BI-RADS 1 and 2 no further work-up is required. The work-up for BI-RADS 4 and 5 requires an invasive procedure (biopsy). The diagnostic work-up of a BIRADS 3 lesion (chance of malignancy 5 cm), clinical symptoms or laboratory values suggesting the presence of metastases [9, 10]. In the case of proven breast cancer, imaging modalities can have an added value not only to determine the extent of the disease but also to characterize the primary and metastatic breast lesions. Non-invasive modalities are increasingly implemented in standard care to support breast cancer diagnosis, staging and evaluation. However, the role of several potential imaging investigations has not yet been fully established and existing international guidelines are lagging behind these developments. The purpose of this editorial is to provide guidance for the application of (developing) imaging techniques in (1) the non-invasive work-up of breast lesions and (2) staging and characterization of advanced breast cancer. M. D. Dorrius Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

[1]  M. Oudkerk,et al.  The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging , 2011, European Radiology.

[2]  A. Verbeek,et al.  Large increase in a Dutch woman's lifetime risk of developing breast cancer. , 2008, European journal of cancer.

[3]  D. Fuster,et al.  Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Wolfgang Bogner,et al.  Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study , 2014, Clinical Cancer Research.

[5]  D. Le Bihan,et al.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.

[6]  U. Topal,et al.  MR imaging in probably benign lesions (BI-RADS category 3) of the breast. , 2006, European journal of radiology.

[7]  J. Benlloch,et al.  Molecular Imaging in Breast Cancer , 2012, Journal of oncology.

[8]  M. J. van de Vijver,et al.  Diagnosis of breast cancer: contribution of US as an adjunct to mammography. , 1999, Radiology.

[9]  Wendy B DeMartini,et al.  BREAST IMAGING : Positive Predictive Value of BI-RADS MR Imaging , 2012 .

[10]  Linda Moy,et al.  Is breast MRI helpful in the evaluation of inconclusive mammographic findings? , 2009, AJR. American journal of roentgenology.

[11]  Alessandro Giordano,et al.  Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. , 2014, Clinical breast cancer.

[12]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[13]  D. Miglioretti,et al.  Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography , 2003, Annals of Internal Medicine.

[14]  C. Lehman,et al.  Performance of diagnostic mammography for women with signs or symptoms of breast cancer. , 2002, Journal of the National Cancer Institute.

[15]  M. Reza,et al.  A systematic review of FDG-PET in breast cancer , 2010, Medical oncology.

[16]  T. Helbich,et al.  Improved Diagnostic Accuracy With Multiparametric Magnetic Resonance Imaging of the Breast Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Diffusion-Weighted Imaging, and 3-Dimensional Proton Magnetic Resonance Spectroscopic Imaging , 2014, Investigative radiology.

[17]  D. Vanel The American College of Radiology (ACR) Breast Imaging and Reporting Data System (BI-RADS): a step towards a universal radiological language? , 2007, European journal of radiology.

[18]  W. Brenner,et al.  Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  N. Hylton,et al.  Magnetic resonance imaging of the breast prior to biopsy. , 2004, JAMA.

[20]  D. Narayanan,et al.  Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  C. Kuhl,et al.  Assessment of BI-RADS category 4 lesions detected with screening mammography and screening US: utility of MR imaging. , 2015, Radiology.

[22]  M. Oudkerk,et al.  Effect of b value and pre-admission of contrast on diagnostic accuracy of 1.5-T breast DWI: a systematic review and meta-analysis , 2014, European Radiology.

[23]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[24]  M. Oudkerk,et al.  The negative predictive value of breast Magnetic Resonance Imaging in noncalcified BIRADS 3 lesions. , 2012, European journal of radiology.

[25]  Shuixing Zhang,et al.  Intravoxel incoherent motion (IVIM) in evaluation of breast lesions: comparison with conventional DWI. , 2013, European journal of radiology.

[26]  Karel G M Moons,et al.  Meta-analysis of MR imaging in the diagnosis of breast lesions. , 2008, Radiology.

[27]  Paul Kinahan,et al.  Clinical Imaging Characteristics of the Positron Emission Mammography Camera: PEM Flex Solo II , 2009, Journal of Nuclear Medicine.

[28]  Myles A Brown,et al.  PET imaging of oestrogen receptors in patients with breast cancer. , 2013, The Lancet. Oncology.

[29]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .